Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q07973
UPID:
CP24A_HUMAN
Alternative names:
Cytochrome P450 24A1; Cytochrome P450-CC24
Alternative UPACC:
Q07973; Q15807; Q32ML3; Q5I2W7
Background:
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial, also known as Cytochrome P450 24A1 or Cytochrome P450-CC24, plays a pivotal role in vitamin D catabolism and calcium homeostasis. It catalyzes the inactivation of vitamin D metabolites through C24- and C23-oxidation pathways, leading to the formation of calcitroic acid and 25(OH)D3-26,23-lactone, respectively.
Therapeutic significance:
The protein's involvement in Hypercalcemia, infantile, 1, a disorder marked by elevated calcium levels and nephrocalcinosis, underscores its therapeutic potential. Targeting Cytochrome P450 24A1 could offer new avenues for treating calcium homeostasis disorders.